Revenue and net profit declined year-over-year, but recurring revenues and radio-pharmaceutical sales grew strongly. EBITDA margin improved, and the group expanded its product portfolio and geographic reach, including new exclusive distribution agreements and an IT acquisition.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.